These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38789306)

  • 1. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
    Vynckier P; Annemans L; Raes S; Amrouch C; Lindgren P; Májek O; Beyer K; Leenen RCA; Venderbos LDF; Denijs F; van Harten MJ; Helleman J; Chloupková R; Briers E; Vasilyeva V; Rivas JG; Basu P; Chandran A; van den Bergh RCN; Collen S; Van Poppel H; Roobol MJ;
    Eur Urol; 2024 May; ():. PubMed ID: 38789306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
    Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
    JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.
    Hao S; Discacciati A; Eklund M; Heintz E; Östensson E; Elfström KM; Clements MS; Nordström T
    JAMA Oncol; 2022 Nov; 9(1):88-94. PubMed ID: 36355382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
    Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
    Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
    Getaneh AM; Heijnsdijk EA; de Koning HJ
    Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Narrative Synthesis of Economic Evaluations of Prostate Cancer Diagnostic Pathways Incorporating Prebiopsy Magnetic Resonance Imaging.
    Merriel SWD; Hall R; Walter FM; Hamilton W; Spencer AE
    Eur Urol Open Sci; 2023 Jun; 52():123-134. PubMed ID: 37213242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study.
    Hao S; Heintz E; Östensson E; Discacciati A; Jäderling F; Grönberg H; Eklund M; Nordström T; Clements MS
    Eur Urol; 2022 Jul; 82(1):12-19. PubMed ID: 35094896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer screening with digital mammography for women at average risk for breast cancer, magnetic resonance imaging (MRI) for women at high risk: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(3):1-55. PubMed ID: 23074406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of screening for chronic kidney disease in the general adult population: a systematic review.
    Yeo SC; Wang H; Ang YG; Lim CK; Ooi XY
    Clin Kidney J; 2024 Jan; 17(1):sfad137. PubMed ID: 38186904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis.
    Gulati R; Jiao B; Al-Faouri R; Sharma V; Kaul S; Fleishman A; Wymer K; Boorjian SA; Olumi AF; Etzioni R; Gershman B
    Ann Intern Med; 2024 Jul; 177(7):871-881. PubMed ID: 38830219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
    Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
    BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.